Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 30, 2004 Charly Travers	Genentech: Priced for Perfection Can Genentech's earnings growth keep up with its valuation? The launch of three new products in the last nine months has made Genentech a very popular, and expensive, company.
The Motley Fool May 5, 2008 Rich Smith	Before the Call: NYSE's Euro-Next Report What do the 100,000 Motley Fool CAPS investors have to say about the New York Stock Exchange shares? Read on to see.
The Motley Fool January 25, 2007 Charly Travers	The Best Drug Stock for 2007 Is ... Is anyone surprised that the largest biotech company in the world, Genentech, came out on top?
The Motley Fool July 15, 2008 Brian Lawler	Genentech Needs More Profit Power Another fine quarter of sales for the biotech company, but what about net earnings?
The Motley Fool August 12, 2010 Jordan DiPietro	7 Burned-Out Drug Stocks These 5-star drug stocks have been beaten down to attractive levels.
The Motley Fool March 31, 2009	3 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: Maxlife Fund... Doral Financial...
The Motley Fool January 29, 2010 Selena Maranjian	Ignore These Financial Advisors Their turn toward the bullish really doesn't matter. Getting too confident about the market's chances can ultimately hurt our investing performance.
The Motley Fool October 19, 2007 Tim Beyers	Hot Stocks You're Buying Now The top three performing industries in the past 30 days have been dry-bulk shipping, Chinese Industries, and Greek companies. Here are some of the hottest stocks in those segment: Omega Navigation Enterprises... China Fire & Security...Navios Maritime...
The Motley Fool November 23, 2009	Commercial Vehicle Group, Inc.: Warming Up or Cooling Off? Take the temperature of your stock.
The Motley Fool November 23, 2009	Casual Male Retail Group, Inc.: Warming Up or Cooling Off? What we think about the direction of this company's stock.
The Motley Fool April 14, 2008 Brian Lawler	Not a Bad Quarter for Genentech Two of its top drugs see speedy growth, but investors don't seem ecstatic about Genentech's first-quarter financial results.
The Motley Fool January 11, 2005 W.D. Crotty	Genentech's Pricey DNA The company continues to churn out sales and earnings gains, but it looks richly priced.
The Motley Fool March 18, 2009 Brian Orelli	Merck Pummels Pfizer One of these acquisitions is not like the other.
The Motley Fool August 6, 2008 Dan Dzombak	3 Stocks Hitting High Notes These stocks are bucking the trend and hitting new highs. Take a look at: Wal-Mart... Marsh & McLennan... Genentech...
The Motley Fool July 21, 2008 Brian Lawler	Roche Wants to Buy Genentech -- Again In what could become one of the biggest biotech deals ever, Roche announces that it is offering to pay $43.7 billion for the remaining Genentech shares it doesn't already own.
The Motley Fool December 22, 2009	9 Cheap Stocks Our Experts Adore Are they right for you? Maybe we've found a few stocks for all you bargain hunters out there.
The Motley Fool July 12, 2007 Brian Lawler	Is It Time to Buy Genentech Yet? Genentech announces positive second-quarter results, but investors remain worried.
The Motley Fool July 18, 2008 Dan Dzombak	3 Stocks Hitting High Notes These stocks are bucking the trend
The Motley Fool January 19, 2007 Stephen Albainy-Jenei	The Best Drug Stock for 2007: Genentech Now that growth is starting to level off for Genentech's four main oncology drugs, many analysts have lowered their ratings and cooled on Genentech's future. But the company is more than just a list of drugs.
The Motley Fool January 12, 2007 Brian Lawler	Genentech on a Roll 2006 was a great year for the world's largest biotech firm. Investors should follow Genentech closely, as the company's a bellwether for the rest of the biopharmaceutical sector.
The Motley Fool March 30, 2009	2 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: American Ecology Corp... Doral Financial Corp. ...
The Motley Fool October 16, 2007 Brian Lawler	Genentech Fitting Better Cancer treatment Avastin continues to surge for the biopharma with a jump on the competition. Investors, take note.
BusinessWeek November 25, 2009 Arlene Weintraub	Can Roche Leave Genentech Alone? Now that Roche has acquired the biotech superstar, success will depend on keeping some distance.
The Motley Fool January 26, 2009 Anders Bylund	Foolish Forecast: Yahoo!'s Last Yodel? In advance of Yahoo!'s earnings report, let's take a look at some of their peers and competitors.
The Motley Fool April 30, 2009 Tim Beyers	Stocks the Rich Executives Are Buying Sometimes insiders are buying for all the right reasons. Who's at it this week?
The Motley Fool November 9, 2006 Shruti Basavaraj	The Best Blue Chip for 2007: Johnson & Johnson If you're out looking for the best blue chip money can buy, consider Johnson & Johnson. The stock combines strong growth opportunities with stability. It's the ideal stock to build the core of your portfolio.
The Motley Fool January 30, 2008 Anders Bylund	Foolish Forecast: Google Will Come Back In advance of Google's quarterly report, let's take a look at the company compared to some of its peers and competitors.
The Motley Fool April 29, 2008 Rich Duprey	Surprising Low-Rated Stocks the Leaders Love See which companies the best CAPS players recommend now.
The Motley Fool February 27, 2009	3 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: Fortune Brands... Martek Biosciences... EZCORP...
The Motley Fool April 7, 2009	3 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: United States Natural Gas Fund... Arena Pharmaceuticals...
The Motley Fool July 11, 2011	Washington Federal Earnings Preview Washington Federal didn't hit the Street's expectations last quarter, but investors hope that it will rebound this quarter. The company will unveil its latest earnings on Thursday.
The Motley Fool February 19, 2010 Amanda B. Kish	Are Insiders Buying or Selling? These signs are encouraging for some companies, but not others.
The Motley Fool December 18, 2008	3 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce?
The Motley Fool May 17, 2011 Luke Timmerman	Merck, Genentech Team Up on Hepatitis C Drug Merck pulling lots of strings to grab market share against Vertex.
The Motley Fool December 31, 2008 Brian D. Pacampara	4-Star Stocks Poised to Pop: General Cable Market-trouncing returns could be written in this 4-star.
The Motley Fool July 12, 2005 Charly Travers	Genentech Shines On The world's largest biotech has been a four-bagger since 2003. Is it too late to get in the game?
BusinessWeek May 9, 2005 Catherine Arnst	Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents.
The Motley Fool June 21, 2005 Brian Gorman	Genentech Hedges Its Edge The company's manufacturing capacity may allow it to attract biotech partners for years into the future. Investors, take note.
The Motley Fool April 10, 2006 Rich Smith	Foolish Forecast: Genentech Under the Microscope Despite Genentech's gross margins declining somewhat over the past 18 months, the company has consistently expanded its operating and net margins. Investors, take note.
The Motley Fool May 25, 2005 Tom Taulli	Genentech's Vision Thing Genentech has been on fire. Now the challenge will be to manage the growth. Investors, take note.
The Motley Fool December 4, 2008 Brian Orelli	Drug Deals Require Cash Pharmaceutical companies have been hoarding cash -- patiently waiting for good prices. And it looks like that time has arrived. Take a look at some players in the pharmaceutical field.
The Motley Fool March 23, 2004 David Nierengarten	Genentech's Star Power How much higher can Genentech go?
The Motley Fool December 12, 2005 Shannon Zimmerman	Genentech: Good Company, Bad Investment Stock valuations in the biotech industry are expensive in general, but on a trailing-12-month basis, Genentech's price-to-earnings, price-to-book, price-to-sales, and price-to-cash flow figures all dwarf those of the broader market. If the price isn't right, buyer beware.
The Motley Fool December 18, 2009 Brian Orelli	2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond.
BusinessWeek December 22, 2003 Robert Barker	A Stimulant For Depressed Drug Stocks? For a bunch of can't-miss stocks, the big drugmakers sure did miss out on 2003's bull run. The dozen drug companies in the Standard & Poor's 500-stock index have returned 10% this year, vs. the index' 22%. But the market is now failing to credit the companies' strengths.
The Motley Fool February 25, 2009 Brian Orelli	Will It Ever End? Genentech's Special Committee of its Board of Directors recommended that investors reject Roche's most recent tender offer.
The Motley Fool October 13, 2010 Jordan DiPietro	3 Sinking Stocks for Savvy Investors These three socks may be ready to climb.
The Motley Fool April 13, 2007 Brian Lawler	Genentech Is Still Healthy The biopharma powerhouse announces its first-quarter financial results. Investors, take note.
The Motley Fool July 1, 2009 Dan Caplinger	These Are Stocks You Need to Own Small-caps outdid their large-cap brethren in the second quarter.
The Motley Fool March 24, 2009 Dan Caplinger	Why Small Caps Are Safer Than You Think While large companies will reel from the past year's implications for a long time to come, small companies are already in position to benefit.